EFTA00599643.pdf

BioReference PRELIMINARY LABORATORIES D 0 T C R FISCH, HARRY C1720 - HARRY FISCH, M.D. NEW YORK, NY 10028 Acct #: (C1720) P: S1 L EPSTEIN, JEFFREY P DOB: 01/20/1953 Age: 63 y Sex: M A U/FL: Bed: T Rm: I Patient ID: E Address:9 EAST 71ST STREET, N NEW YORK, NY 10021 P: (212)772-9416 (Notes: NON FASTING 1 Specimen ID: 102449709 Date Of Report: 01/28/2016 02:32 Date Collected: 01/27/2016 12:37 Date Received: 01/27/2016 23:01 North America Eastern Time CLINICAL REPORT Clinical Abnormalities Summary: (May not contain all abnormal results; narrative results may not have abnormal flags. Please review entire report.) Triglycerides INTR.NORM. RATIO(INR) PROLACTIN, SERUM 459 HI 0.97 LO 3.0 LO HDL CHOL., DIRECT 24 LO Hemoglobin A1C 6.0 HI * CHEMISTRY * Test Result Abnormal e erence In s •rev ous •esu la e Total Protein 6.7 5.9-8.4 g/dL 7.1 10/27/2015 Albumin 4.2 3.5-5.2 g/dL 4.6 10/27/2015 Globulin 2.5 1.7-3.7 g/dL 2.5 10/27/2015 AA Ratio 1.7 1.1-2.9 1.8 10/27/2015 Glucose 99 70-99 mg/dL 95 10/27/2015 Sodium 141 135-147 mmol/L 135 10/27/2015 NOTE: New reference range for Sodium effective 11/16/15. Potassium 4.2 3.5-5.5 mmol/L 4.2 10/27/2015 NOTE: New reference range for Potassium effective 11/16/15. Chloride 102 96-108 mmol/L 96 10/27/2015 CO2 26 22-29 mmol/L 26 10 27 2015 BUN 22 8-23 mg/dL 21 10/27/2015 Creatinine 1.11 0.80-1.30 mg/dL 1.03 10/27/2015 e-GFR 70 >or-60 mL/min 77 10/27/2015 e-GFR, African American 81 >or=60 mL/min 89 10/27/2015 BUN/Creat Ratio 19.8 10.0-28.0 20.4 10/27/2015 Calcium 9.8 8.6-10.4 mg/dL 9.7 10/27/2015 Uric Acid 7.5 3.4-8.5 mg/dL 6.2 10/27/2015 Iron 75 45-160 ug/dL 57 10/27/2015 Bilirubin, Total 0.5 <1.2 mg/dL 0.5 10/27/2015 LD 171 135-225 U/L 177 10/27/2015 Alk Phos 43 40-156 U/L 62 10/27/2015 AST 29 <40 U/L 23 10/27/2015 PHOSPHORUS 3.4 2.7-4.5 mg/dL 3.3 10/27/2015 ALT 29 <41 U/L 25 10/27/2015 GGTP 18 10-71 U/L 15 10/27/2015 -* CARDIOVASCULAR/LIPIDS *-- Cholesterol 143 <200 mg/dL 210 HI 10/27/2015 BioReference Laboratories, Inc. Elmwood Park, N3 07407 James Weisberger M.D. Page 1 of S Labcwatory[WW0C Printed 01/28/2016 15:30 EFTA00599643 BioReference D LABORATORIES T C R FISCH, HARRY C1720 - HARRY FISCH, M.D. NEW YORK, NY 10028 Acct #: C1720 P: S1 I I T EPSTEIN, JEFFREY P DOB: 01/20/1953 Age: 63 y Sex: M A U/FL: Bed: T Rm: I Patient ID: E Address:9 EAST 71ST STREET, N NEW YORK, NY 10021 P: (212)772-9416 PRELIMINARY 1 Specimen ID: 102449709 Date Of Report: 01/28/2016 02:32 Date Collected: 01/27/2016 12:37 Date Received: 01/27/2016 23:01 North America Eastern Time ./ CLINICAL REPORT Test Result Abnormal Reference Units Previous Result Date Triglycerides 459 HI <150 mg/dL 348 HI 10/27/2015 HDL CHOL., DIRECT 24 LO >40 mg/dL 29 LO 10/27/2015 HDL as % of Cholesterol 17 >14 % 14 * 10/27/2015 Evaluation: AVERAGE RISK Chol/HDL Ratio 6.0 <7.4 I 7.2 10/27/2015 Evaluation: AVERAGE RISK LDL/HDL Ratio Can't Calc <3.56 3.83 HI 10/27/2015 LDL Cholesterol Can't Calc <100 mg/dL 2/2 HI 10/27/2015 NOTE: Unable to calculate LDL due to a Triglyceride level of greater than 400 mg/dL. VLDL, CALCULATED Can't Calc 7-32 mg/dL I 70 HI 110/27/2015 Can't Calc: One or more components was outside the measurable range. We are unable to calculate. * HEMATOLOGY * WBC 7.12 3.40-11.80 x10(3)/uL 6.33 10/27/2015 RBC 4.96 4.20-5.90 x10(6)/uL 5.01 10/27/2015 HGB 14.3 12.3-17.0 gm/dL 14.6 10/27/2015 HCT 41.3 39.3-52.5 % 41.9 10 27 2015 MCV 83.3 80.0-100.0 fL 83.6 10/27/2015 MCH 28.8 25.0-34.1 pg 29.1 10/27/2015 MCHC 34.6 29.0-35.0 gm/dL 34.8 10/27/2015 RDW 13.9 10.9-16.9 % 14.4 10/27/2015 POLYS 49.2 36.0-78.0 % 51.1 10/27/2015 LYMPHS 36.2 12.0-48.0 % 37.1 10/27/2015 MONOS 7.6 0.0-13.0 5.8 10/27/2015 COS 6.5 0.0-8.0 % 5.4 10/27/2015 BASOS 0.4 0.0-2.0 % 0.6 10/27/2015 IMMATURE GRANULOCYTES 0.1 0.0-1.6 0.0 10/27/2015 Platelet Count 222 144-400 x10(3)/uL 257 10/27/2015 MPV 9.5 8.2-11.9 fL 9.0 10/27/2015 PT 10.1 9.1-11.9 sec 10.0 LO 10/27/2015 NOTE: New reference range for Protime effective 11/10/15. INTR.NORM.RATIO(INR) 0.97 LO 2.00-3.00 0.92 LO 10/27/2015 CLINICAL INDICATIONS FOR INR USE BioReference Laboratories, Inc. Elmwood Park. NJ 07407 JannesINeisbergerM.D. Page 2 of 5 Laboratory Director printed 01/28/2016 15:30 EFTA00599644 BioReference LABORATORIES FISCH, HARRY EPSTEIN, JEFFREY I, DOB: 21:20/1953 Age: 63 y Sex: M D 0 1720 - HARRY FISCH, M.D. A U/FL: Bed: C I Rm: T I Patient ID: R NEW YORK, NY 10028 Acct #: (C1720) 51 P: E Address:9 EAST 71ST STREET, N NEW YORK, NY 10021 I P: (212)772-9416 PRELIMINARY 1 Specimen ID: 102449709 Date Of Report: 01/28/2016 02:32 Date Collected: 01/27/2016 12:37 Date Received: 01/27/2016 23:01 North Americo Eastern Time CLINICAL REPORT Test Result Abnormal Reference Units I Previous Result' Date Reference Range Prophylaxis or treatment of venous thrombosis, 2.00.3.00 systemic embolization, and pulmonary embolus High-risk patients with mechanical heart valves 2.50-3.50 Normal Non-Medicated patients 0.87-1.15 (effective 11.10.15) NOTE: INR values below 2.00 for patients on warfarin therapy would be considered sub-therapeutic for the above conditions. PTT 26.5 23.6-31.6 sec I 27.6 110/27/2015 NOTE: The modified activated Partial Thromboplastin Time (APTT) is a screening procedure for assessment of secondary coagulation, e.g. whether sufficent fibrinogen and plasma factors are present in amounts for adequate hemostasis. The extension of the stability to 24 hours for the APTT is only valid in its use as an initial screening assay of non-hospitalized patient population. Assessment of factor assays, unfractionated heparin monitoring, mixing studies, and evaluation for antiphospholipid-associated APTT abnormalities ("Lupus anticoagulant") requires strict frozen plasma. a MISCELLANEOUS * TSH 1.790 0.178-4.530 uIU/mL 2.060 10 27 2015 THYROXINE(T4) 6.3 4.9-12.9 ug/dL 7.5 10/27/2015 T3 UPTAKE (T3U) 29.3 24.3-39.0 X 29.1 10/27/2015 THYROXINE, FREE (FT4) 0.93 0.80-1.73 ng/dL 1.06 10/27/2015 FREE T4 INDEX 1.8 1.5-3.8 2.2 10 27 2015 T3 (THYRONINE), TOTAL 127 72-180 ng/dL 129 10/27/2015 PSA Total 0.70 <4.00 ng/mL 0.87 10/27/2015 NOTE: The PSA assay should not be the only test used for diagnostic purposes. Additional evaluation using DRE, ultrasound, TUR or similar procedures may be used for this purpose. Predictions of disease recurrence should not be based solely upon values obtained from serial PSA values obtained on the patient. NOTE: Values obtained with different assay methods or kits cannot be used interchangeably. NOTE: Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics) PSA, FREE 0.33 Not Estab. ng/mL I 0.31 10/27/201S BioReference Laboratories, Inc. Elmwood Park, NJ 07407 James Weisberger M.D. Page 3 of S Laboratory Director Printed 01/28/2016 15:30 EFTA00599645 BioReference n —s LABORATORIES FISCH, HARRY EPSTEIN, JEFFREY p DOB: 21/20/1953 Age: 63 y Sex: M D 0 C1720 - HARRY FISCH, M.D. A U/FL: Bed: C T Rm: T I Patient ID: R NEW YORK, NY 10028 Acct #: (C1720) P: Si E Address:9 EAST 715T STREET, N NEW YORK, NY 10021 T P: (212)772-9416 PRELIMINARY 1 Specimen ID: 102449709 Date Of Report: 01/28/2016 02:32 Date Collected: 01/27/2016 12:37 Date Received: 01/27/2016 23:01 North America Eastern Time CLINICAL REPORT Test Result Abnormal e erence n s rev ous esu a e NOTE: Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. Values obtained with different assay methods or kits cannot be used interchangeably. ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics). % FREE PSA 47 See Below % 36 10/27/2015 FREE PSA RISK ASSESSMENT The probability of prostate cancer for men with non-suspicious DRE results, by age group, using PSA values between 4.000 and 10.000 ng/mL and percent FREE PSA values is summarized in the table below: PROBABILITY OF CANCER* %free PSA (50-59 yrs) (60-69 yrs) (>or.70 yrs) <or-t0 49.2% 57.5% 64.5% 11-18 26.9% 33.9% 40.8% 19-25 18.3% 23.9% 29.7% >25 9.1% 12.2% 15.8% *probability of finding prostate cancer by needle biopsy NOTE: Calculation of percent FREE PSA may not be possible when the value for TOTAL PSA is in the low normal range. These guidelines are for assays performed using the Roche E170 immunoassay system.(02/2012;v5) TESTOSTERONE, TOT.,S. 296.0 193.0-740.0 ng/dL 112.3 LO 10/27/2015 TESTOSTERONE, BIOAVAIL. 183.8 72.0-460.0 ng/dL 74.6 10/27/2015 SEX HORM.BIND.GLOB. 18 10-57 nmol/L 14 10/27/2015 FREE TESTOSTERONE 80.18 30.00-150.00 pg/mL 29.82 LO 10/27/2015 LH 6.8 1.7-8.6 mIU/mL 3.7 10/27/2015 FSH 6.8 1.5-12.4 mIU/mL 4.8 10/27/2015 PROLACTIN, SERUM 3.0 LO 4.0-15.2 ng/mL 3.4 LO 10/27/2015 ESTRADIOL 48.93 7.02-49.06 pg/mL 16.00 10/27/2015 FIBRINOGEN 276 176-441 mg/dL 362 10/27/2015 Hemoglobin A1C 6.0 HI <5.7 % 5.9 HI 10/27/2015 HEMOGLOBIN A1c AND eAG REFERENCE RANGES A1c(%) DIABETES CATEGORY* <5.7 Normal (non-diabetic) 5.7-6.4 Increased risk of diabetes .>6.5 Consistent with diabetes A1c(%) eAG(ESTIMATED AVERAGE PLASMA GLUCOSE)(mg/dL) BioReference Laboratories, Inc. Elmwood Park, NJ 07407 I James Weisberger M.D. Page 4 of 5 Laboratory Director Printed 01/28/2016 15:30 EFTA00599646 BioReference PRELIMINARY LABORATORIES D 0 T C R FISCH, HARRY C1720 - HARRY FISCH, M.D. NEW YORK, NY 10028 Acct #: (C1720) P: Si I T EPSTEIN, JEFFREY P DOB: 01/20/1953 Age: 63 y Sex: M U/FL: Bed: T Rm: I Patient ID: E Address:9 EAST 71ST STREET, N NEW YORK, NY 10021 P: (212)772-9416 1 Specimen ID: 102449709 Date Of Report: 01/28/2016 02:32 Date Collected: 01/27/2016 12:37 Date Received: 01/27/2016 23:01 North America Eastern Time CLINICAL REPORT Test Result Abnormal Reference Units 6 126 7 154 8 183 9 212 10 240 11 269 12 298 *recommended ranges-American Diabetes Association(2010) I Previous Result] Date NOTE: Hemolysis, rare hemoglobin variants and thalassemia major may affect glycemic results. DIHYDROTESTOSTERONE TO FOLLOW SEE REPORT 153.0 10/27/2015 BioReference Laboratories, Inc. I Elmwood Park, NJ 07407 I Page 5 of 5 JamesVAnsbmueraD. LaborMoryDkoMor Printed 01/28/2016 15:30 EFTA00599647